Buy the report "Bioinformatics Partnering Terms and Agreements" at US $2795 for a Single User PDF License from RnR Market Research Reports Library. The report provides a detailed understanding and analysis of how and why companies enter bioinformatics partnering deals.
Unlocking the Power of ChatGPT and AI in Testing - A Real-World Look, present...
Bioinformatics Terms and Agreements 2013
1. RnR Market Research Offers “Bioinformatics Partnering Terms and Agreements” Report
at US$ 2795 (Single User License). The report got published in Mar 2013 & Contains 1154
Pages.
The Bioinformatics Partnering Terms and Agreements report provides comprehensive understanding and
unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds
leading healthcare companies.
- Trends in bioinformatics partnering deals
- Deal terms analysis
- Partnering agreement structure
- Partnering contract documents
- Top deals by value
- Most active dealmakers
- Average deal terms for bioinformatics
The Bioinformatics Partnering Terms and Agreements report provides comprehensive understanding and
unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds
leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter
bioinformatics partnering deals. The majority of deals are discovery stage whereby the licensee obtains a
right or an option right to license the licensors bioinformatics technology. These deals tend to be
multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest bioinformatics agreements announced in the healthcare sectors.
Bioinformatics is the application of computer science and information technology to the field of biology
and medicine. Bioinformatics deals with algorithms, databases, information systems, web technologies,
artificial intelligence, information and computation theory, software engineering, data mining, image
processing, modeling, simulation, signal processing, discrete mathematics, control systems, and
statistics, for generating new knowledge of biology and medicine.
Bioinformatics deals have increased in terms of popularity for partnering in the past decade, as computing
power has been embraced in order to speed up the discovery, evaluation and clinical assessment
processes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into
the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst
many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms
of how payments are triggered – contract documents provide this insight where press releases and
databases do not.
Request a Sample Copy @ http://www.rnrmarketresearch.com/contacts/request-
sample?rname=82679
This report contains a comprehensive listing of all bioinformatics partnering deals announced since
January 2007, including financial terms where available, including over 1500 links to online deal records
of actual bioinformatics partnering deals as disclosed by the deal parties. In addition, where available,
records include contract documents as submitted to the Securities Exchange Commission by companies
2. and their partners.
The initial chapters of this report provide an orientation of bioinformatics dealmaking and business
activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the
trends in bioinformatics dealmaking since 2007, including details of average headline, upfront, milestone
and royalty terms.
Chapter 3 provides a review of the leading bioinformatics deals since 2007. Deals are listed by headline
value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where
the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary
followed by a comprehensive listing of bioinformatics deals, as well as contract documents available in
the public domain. Where available, each deal title links via Weblink to an online version of the actual
contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of bioinformatics partnering deals signed and
announced since January 2007, where a contract document is available in the public domain. The
chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion,
licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal
record and where available, the contract document, providing easy access to each contract document on
demand.
In addition, a comprehensive appendix is provided organized by bioinformatics partnering company A-Z ,
deal type definitions and bioinformatics partnering agreements example. Each deal title links via Weblink
to an online version of the deal record and where available, the contract document, providing easy access
to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in
bioinformatics partnering and dealmaking since 2007.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in
the research, development and commercialization of bioinformatics technologies and products.
Bioinformatics Partnering Terms and Agreements provides the reader with the following key
benefits:
- In-depth understanding of bioinformatics deal trends since 2007
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of bioinformatics agreements with numerous real life case studies
- Comprehensive access to over 1500 actual vaccine contracts entered into by the world’s biopharma
companies
- Detailed access to actual bioinformatics contracts enter into by the leading fifty bigpharma companies
- Insight into the terms included in a bioinformatics agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope
Bioinformatics Partnering Terms and Agreements is intended to provide the reader with an in-depth
understanding and access to bioinformatics trends and structure of deals entered into by leading
companies worldwide.
3. Bioinformatics Partnering Terms and Agreements includes:
- Trends in bioinformatics dealmaking in the biopharma industry since 2007 Analysis of bioinformatics
deal structure
- Access theadline, upfront, milestone and royalty data Case studies of real-life bioinformatics deals
Access tover 1500 bioinformatics contract documents
- The leading bioinformatics deals by value since 2005 Most active bioinformatics dealmakers since 2007
- The leading bioinformatics partnering resources In Bioinformatics Partnering Terms and Agreements,
the available contracts are listed by: Company A-Z Headline value
- Stage of development at signing Deal component type
- Specific therapy target Each deal title links via Weblink tan online version of the deal record and where
available, the contract document, providing easy access teach contract document on demand.
The Bioinformatics Partnering Terms and Agreements report provides comprehensive access tavailable
deals and contract documents for over 1,500 bioinformatics deals.
Analyzing actual contract agreements allows assessment of the following:
- What are the precise bioinformatics rights granted or optioned?
- What is actually granted by the agreement tthe partner company?
- What exclusivity is granted?
- What is the payment structure for the deal? How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned? Whis responsible for commercialization?
- Which responsible for development, supply, and manufacture?
- How is confidentiality and publication managed? How are disputes tbe resolved?
- Under what conditions can the deal be terminated? What happens when there is a change of
ownership?
- What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does
the company insist upon?
- Which boilerplate clauses appear tdiffer from partner tpartner or deal type tdeal type?
- Which jurisdiction does the company insist upon for agreement law?
Number of pages: The report is comprised of two volumes with the second volume containing the
appendices totaling 1154 pages.
Bioinformatics Partnering Terms and Agreements provides the reader with the following key
benefits:
- In-depth understanding of bioinformatics deal trends since 2007
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of bioinformatics agreements with numerous real life case studies
- Comprehensive access to over 1500 actual bioinformatics contracts entered into by the world’s
biopharma companies
- Detailed access to actual bioinformatics contracts enter into by the leading fifty bigpharma companies
- Insight into the terms included in a bioinformatics agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Buy a Report Copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=82679
4. Table of Content
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in bioinformatics dealmaking
Chapter 3 – Leading bioinformatics deals
Chapter 4 – Bigpharma bioinformatics deals
Chapter 5 – Bioinformatics dealmaking directory
Chapter 6 – Partnering resource center
About Wildwood Ventures
For more details contact Mr. Priyank Tiwari: sales@rnrmarketresearch.com / +18883915441
Website: http://www.rnrmarketresearch.com/